HER2 expressing metastatic solid tumors such as breast cancer and gastro-esophageal adenocarcinoma will be evaluated with HER2-PET and [68Ga]Ga-ABY-025 in this trial. The gene discussed is ERBB2; the disease is breast carcinoma.